Overview

Calcitriol Supplementation in COVID-19 Patients

Status:
Not yet recruiting
Trial end date:
2022-09-19
Target enrollment:
0
Participant gender:
All
Summary
This is a randomized, open label study to evaluate the efficacy and safety of calcitriol supplementation in COVID-19 patients with vitamin D deficiency.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
RenJi Hospital
Treatments:
Calcitriol
Criteria
Inclusion Criteria:

1. Hospitalized symptomatic COVID-19 patients;

2. COVID-19 nucleic acid Ct value < 28 (both orf1ab gene Ct value and N gene Ct value <
28);

3. Vitamin D deficiency: 25OHD ≤ 20ng/ml;

4. Age: 18-70 years old;

Exclusion Criteria:

1. Asymptomatic COVID-19 patients ;

2. Hypercalcemia;

3. History of primary hyperparathyroidism;

4. History of triple hyperparathyroidism;

5. Patients who are allergic to calcitriol;

6. Pregnant or lactating women;

7. Patients with severe heart or lung diseases or tumor history;

8. Patients already taking vitamin D or its similar preparations;

9. Participants in other interventional clinical studies (including taking paxlovid);

10. Patients with renal insufficiency (eGFR<60ml/min/1.73m2);

11. Patients considered unsuitable for this study by the investigator;